Previous clinical studies of BCL2/Bcl-xL inhibitor navitoclax in patients with CLL and small cell lung cancer demonstrated thrombocytopenia as a major dose-limiting toxicity, which would militate against the use of navitoclax in combination with ABBV-07550,51. Here, BCL2 is linked to small cell lung carcinoma.